+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Coagulation Testing Market - Forecasts from 2022 to 2027

  • PDF Icon


  • 123 Pages
  • February 2022
  • Region: Global
  • Knowledge Sourcing Intelligence LLP
  • ID: 5576431
The Coagulation Testing market was valued at US$2,715.944 million in 2020 and is expected to grow at a CAGR of 4.16% over the forecast period to reach a total market size of US$3,612.665 million by 2027.

Coagulation tests are conducted to test the hemostasis system. Generally, this test is performed with a coagulometer, which measures and evaluates the rate at which clots form or blood coagulates. A blood clot in a blood vessel can lead to heart attack, thrombosis, or embolism. By performing these tests, one can avoid these unfavourable outcomes.

A growing prevalence of blood disorders and cardiovascular conditions, increase in geriatric population, surging demand for point of care (POC) coagulation testing, and technological advancements such as faster and easier to use devices with advanced sensors have been contributing to the market growth.  According to the United Nations (UN) data of World Population Prospects for 2019, the world's population will double within 30 years, from 7.7 billion to 9.7 billion, and at the same time, it will age more rapidly. The number of people over the age of 65 will rise from one in 11 in 2019 to one in six by 2050 (16%), up from one in 11 at the beginning of this year (9%).  Worldwide, cardiovascular diseases (CVDs) lead to 17.9 million deaths each year, as reported by the WHO.  A steady increase in the population suffering from chronic diseases and blood disorders is currently fueling the coagulation testing demand.

The introduction of new coagulation analyzer tests and rapid advancements in technology have led to an increase in the quality and efficiency of hemostasis laboratories over the past decade. In order to prevent bleeding and excessive coagulation, the liver plays an essential role in hemostasis. The CN-6000 and CN-3000 are fully automated, next-generation blood coagulation analyzers recently launched by Sysmex in the EMEA region. As part of the CN-6000 and CN-3000, which were recently introduced, four new capabilities have been built to cater to the increasingly diverse needs of high-volume hemostasis testing. 

Growth Factors:

Increased prevalence of liver disease:

As the liver is a central player in the clotting process, acute and chronic liver disease frequently leads to coagulation disorders due to a number of factors, such as decreased synthesis of clotting and inhibitor factors, an inability to eliminate activated factors, and defects in both quantity and quality of platelets.  In 2018, the number of deaths from liver diseases reached 49,789, or 2.07% of all deaths in the United States. The number of adults with diagnosed liver disease is 4.5 million, according to the Centres for Disease Control and Prevention (CDC) and there is a 1.8% prevalence of liver disease in adults. In England, liver cancer and liver disease combined were the cause of 2.5% of deaths in 2018. Those who are of working-age make up over half of these deaths. According to the Office for National Statistics, in England in 2018, cirrhosis and other liver diseases accounted for the top five leading causes of death among those aged 20 to 34, and more than 10% of deaths among those aged 35 to 49. Furthermore,  the WHO data released in 2018 showed that there were 264,193 liver disease deaths in India, which represent 3.00% of the total deaths. In light of the high incidence of liver disease around the world, the coagulation testing market will grow at a significant rate during the forecast period.


High cost:

Having a fully automated coagulation system comes at a high cost. Staff members other than hematologists must obtain training and be competent. It is more difficult to establish rigorous quality assurance standards outside the laboratory.  Stringent regulations governing coagulation testing devices, the high cost of fully automatic hemostasis equipment, and the concern over the potential side effects of blood testing are inhibiting the growth of the global market. In addition, the slow adoption of advanced hemostasis instruments and the lack of awareness regarding innovative and advanced applications of coagulation test devices are also hampering the market growth, particularly in developing countries.

COVID-19 Impact Coagulation Testing Market:

The D-dimer level is elevated in COVID-19 patients. Coagulation disorders associated with COVID-19 are more common in patients with serious infections than in patients with mild infections, and those who die of COVID-19 are more likely to meet ISTH criteria compared to survivors. The marked increase in D-dimer levels over time and the rise in D-dimer levels at admission are associated with high mortality, reflecting coagulation activation caused by infection/sepsis, cytokine storm, or progressive organ failure. There are several factors contributing to the coagulation testing market growth, such as the increased awareness of the disease, the benefits of early diagnosis, and the potential to monitor blood flow in people with COVID-19.


By Test Type

  • Prothrombin Time Testing
  • Fibrinogen Testing
  • Activated Clotting Time Testing
  • Platelet Function Tests
  • Other 

By End Users

  • Hospitals and Clinics
  • Diagnostic Centres
  • Ambulatory Care Centres 

By Geography

  • North America
  • United States
  • Canada
  • Others
  • South America
  • Brazil
  • Argentina
  • Others
  • Europe
  • United Kingdom
  • Germany
  • France
  • Others
  • Middle East and Africa
  • Saudi Arabia
  • UAE
  • Israel
  • Others
  • Asia Pacific
  • China
  • India
  • South Korea
  • Taiwan
  • Thailand
  • Indonesia
  • Japan
  • Others
Frequently Asked Questions about the Global Coagulation Testing Market

What is the estimated value of the Global Coagulation Testing Market?

The Global Coagulation Testing Market was estimated to be valued at $2715.94 million in 2020.

What is the growth rate of the Global Coagulation Testing Market?

The growth rate of the Global Coagulation Testing Market is 4.1%, with an estimated value of $3612.67 million by 2027.

What is the forecasted size of the Global Coagulation Testing Market?

The Global Coagulation Testing Market is estimated to be worth $3612.67 million by 2027.

Who are the key companies in the Global Coagulation Testing Market?

Key companies in the Global Coagulation Testing Market include Abbott, Diagnostica Stago, S.A.S., F. Hoffmann, La Roche Ltd, Thermo Fisher Scientific, Enzyme Research Laboratories Ltd, Sekisui Medical Co., Ltd., Stago Group, Coagulation Sciences LLC and RUSNANO Group.

Table of Contents

1. INTRODUCTION1.1. Market Definition
1.2. Market Segmentation

2.2. Assumptions

3. EXECUTIVE SUMMARY3.1. Research Highlights

4. MARKET DYNAMICS4.1. Market Drivers
4.2. Market Restraints
4.3. Porters Five Forces Analysis
4.3.1. Bargaining Power of Suppliers
4.3.2. Bargaining Powers of Buyers
4.3.3. Threat of Substitutes
4.3.4. The threat of New Entrants
4.3.5. Competitive Rivalry in Industry
4.4. Industry Value Chain Analysis

5.2. Prothrombin Time Testing
5.3. Fibrinogen Testing
5.4. Activated Clotting Time Testing
5.5. Platelet Function Tests
5.6. Others 

6.2. Hospitals and Clinics
6.3. Diagnostic Center
6.4. Ambulatory Care Centers7. GLOBAL COAGULATION TESTING MARKET, BY GEOGRAPHY7.1. Introduction
7.2. North America
7.2.1. United States
7.2.2. Canada
7.2.3. Mexico
7.3. South America
7.3.1. Brazil
7.3.2. Argentina
7.3.3. Others
7.4. Europe
7.4.1. Germany
7.4.2. France
7.4.3. United Kingdom 
7.4.4. Spain 
7.4.5. Others
7.5. Middle East and Africa
7.5.1. Saudi Arabia
7.5.2. UAE
7.5.3. Israel
7.5.4. Others
7.6. Asia Pacific
7.6.1. China
7.6.2. India
7.6.3. South Korea
7.6.4. Taiwan
7.6.5. Thailand
7.6.6. Indonesia 
7.6.7. Japan
7.6.8. Others

8. COMPETITIVE ENVIRONMENT AND ANALYSIS8.1. Major Players and Strategy Analysis
8.2. Emerging Players and Market Lucrativeness
8.3. Mergers, Acquisition, Agreements, and Collaborations
8.4. Vendor Competitiveness Matrix

9.2. Diagnostica Stago, S.A.S.
9.3. F. Hoffmann-La Roche Ltd
9.4. Thermo Fisher Scientific
9.5. Enzyme Research Laboratories Ltd
9.6. Sekisui Medical Co., Ltd.
9.7. Stago Group 
9.8. Coagulation Sciences LLC
9.9. RUSNANO Group
9.10. Universal Biosensors

Companies Mentioned

  • Abbott
  • Diagnostica Stago, S.A.S.
  • F. Hoffmann-La Roche Ltd
  • Thermo Fisher Scientific
  • Enzyme Research Laboratories Ltd
  • Sekisui Medical Co., Ltd.
  • Stago Group
  • Coagulation Sciences LLC
  • RUSNANO Group
  • Universal Biosensors